Our research focuses on metabolic signaling and redox adaptation in cancer, centered on PKM2-driven glyco-redox networks that couple glycolysis to ferroptosis vulnerability. We investigate metabolic programs at invasive tumor fronts to identify actionable metabolic liabilities and develop small-molecule inhibitors targeting metabolic and epigenetic regulators, including KDM4 demethylases. Our work also examines glutathione metabolism, SLC7A11/xCT function, and membrane lipid remodeling in redox homeostasis. In parallel, we study host–microbe metabolic interfaces through structural and translational analyses of cholesterol-modifying enzymes and shikimate pathway targets, aiming to define metabolically targetable vulnerabilities.